Modex enters second collaboration with Serono

12 August 2001

Swiss companies Modex Therapeutics and Serono have signed a secondagreement for the engineering of a cell line for the production of a protein of commercial interest. The development will be based on a Modex proprietary system which may result in high protein expression levels.

This two-year program will be entirely funded by Serono, with Modex earning milestone fees of up to 1 million Swiss francs ($584,900) and a percentage of future income derived from the sales of products based on the expressed protein.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight